Month: September 2026

Gross Proceeds of $100,000,000 to Fund Exploration and Development of New Brunswick Properties

Special Warrants Priced at $0.25 per Special Warrant

Canaccord Genuity to Act as Lead Agent and Sole Bookrunner

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — Osisko Critical Minerals Corporation (“OCMC” or the “Corporation“), a newly incorporated entity and a wholly-owned subsidiary of Osisko Metals Incorporated (“Osisko Metals“) (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51), is pleased to announce a best efforts private placement (the “Private Placement“) of special warrants of the Corporation (the “Special Warrants“) at a price of $0.25 per Special Warrant for gross proceeds of $100,000,000. The Private Placement will be led by Canaccord Genuity Corp. (“Canaccord Genuity“), acting as lead agent and sole bookrunner, on behalf of a syndicate of agents (collectively, the “Agents“).

Incoming CEO John Burzynski commented: “We are have had a tremendous reception for OCMC in the capital markets, and the strong investor interest in our new critical minerals company reflects confidence in our exploration portfolio and the significant opportunity we see in New Brunswick. We look forward to completing this offering to capitalize this new venture and to advancing our aggressive exploration program on these highly prospective copper assets.”

Private Placement Terms

Upon satisfaction of the release conditions described below (the “Release Conditions“), each Special Warrant shall automatically convert, without payment of additional consideration, into one unit of the Corporation (each, a “Unit“), with each Unit consisting of one common share of the Corporation (each, a “Common Share“) and one-half of one common share purchase warrant of the Corporation (each whole warrant, a “Warrant“). Each Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.35 per share for a period of 24 months following the closing date of the Private Placement (the “Closing Date“).

The Release Conditions shall mean (i) the receipt for a final prospectus (the “Qualifying Prospectus“) qualifying the distribution of the Common Shares and Warrants underlying the Special Warrants being issued by the securities regulatory authorities in the provinces of Canada in which the Special Warrants are sold; and (ii) the TSX Venture Exchange (the “Exchange“) granting conditional approval to list the Common Shares and Warrants, on or before the date that is 180 days following the Closing Date.

The Corporation intends to use the net proceeds of the Private Placement to fund: (i) exploration and development costs of the properties located in New Brunswick, Canada (the “Properties“); and (ii) general working capital and corporate expenses.

The Private Placement is expected to close on or about November 17, 2026 or such other date as may be mutually agreed upon between Canaccord Genuity and the Corporation (the “Closing Date“).

The Corporation shall use its best efforts to satisfy the Release Conditions as soon as practicable following the Closing Date.

New Brunswick Properties

The Properties comprise an aggregate of 2,972 mineral claim units (approximately 645 square kilometres) staked by the Osisko Metals and claims which it has an option to acquire pursuant to three separate option agreements (collectively, the “Option Agreements“, entered into on January 9, 2026; April 20, 2026; and September 9, 2026 respectively). In connection with the transaction, the Option Agreements will be assigned to the Corporation in exchange for common shares of Corporation. The Properties include several large-scale mineral exploration targets prospective for copper, silver and gold, underlain by highly prospective geology similar in context to the nearby Gaspé Copper Project, and are more particularly described in the news release of Osisko Metals dated September 15, 2026 and titled “Osisko Metals to Create New Critical Minerals Company”.

Additional Information

Bennett Jones LLP is acting as legal advisors to the Corporation in connection with the Go-Public Transaction.

Cassels Brock & Blackwell LLP is acting as legal advisors to the Agents in connection with the Private Placement.

Additional Information

There is no certainty that the Private Placement will be completed on the terms proposed, or at all. Completion of the Private Placement is subject to a number of conditions, including: completion of legal and tax structuring; completion of financial analysis; negotiation and execution of definitive documentation; and required regulatory approvals. There can be no assurance that any securities of the Corporation will be listed on any stock exchange.

Scientific and Technical Disclosure

Qualified Person

The scientific and technical information within this news release was reviewed and approved by Jared Hansen, P.Geo., a “qualified person” within the meaning of NI 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) who is not independent of Osisko Metals for purposes of Section 1.5 of NI 43-101.

About Osisko Critical Minerals Corporation

Osisko Critical Minerals Corporation is a newly incorporated Canadian mineral exploration company focused on the discovery and development of copper and critical minerals deposits. The Corporation’s principal assets are the Properties, comprising approximately 645 square kilometres of mineral claims in northern New Brunswick, Canada. The Properties include the NB Copper Project, which hosts large-scale exploration targets for bulk-tonnage copper deposits in a geological setting analogous to the nearby Gaspé Copper Project. OCMC is led by John Burzynski as Chief Executive Officer and is a wholly-owned subsidiary of Osisko Metals Incorporated pending completion of the Private Placement.

For further information on this news release, contact:

Don Njegovan, President
Email: info@osiskometals.com
Phone: (416) 500-4129

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Any statement that involves predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always, using phrases such as “expects” or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “potential”, “feasibility”, “believes” or “intends”, or variations of such words and phrases, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This news release contains forward-looking information pertaining to, among other things: statements with respect to the terms, timing and outcome of the Private Placement, including the expected closing date; that the Corporation will use the proceeds from the Private Placement to fund exploration and development of the Properties and general working capital; the timing of the satisfaction of the Release Conditions; the anticipated listing of the Common Shares and Warrants on the TSX Venture Exchange; the pre-closing steps to be completed by Osisko Metals, including the transfer of the Properties and the subscription for Units; Osisko Metals’ retention of an interest in the Corporation; receipt of the required regulatory approvals in connection with the Private Placement; the anticipated benefits of the Private Placement; anticipated strategic and growth opportunities; and the future plans and objectives of the Corporation.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, without limitation, assumptions about: completion of the Private Placement, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary approvals for the Private Placement; completion of the Go-Public Transaction and satisfaction of the Release Conditions within the required timeframe; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Private Placement; that the anticipated benefits of the Private Placement will be realized; that general business and economic conditions will not change in a material adverse manner; that financing will be available if and when needed and on reasonable terms; that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Corporation’s planned exploration activities will be available on reasonable terms and in a timely manner; the ability of exploration results, including drilling, to accurately predict mineralization; errors in geological modelling; insufficient data; equity and debt capital markets; future spot prices of minerals; the timing and results of exploration and drilling programs; production costs; political and regulatory stability; the receipt of governmental and third party approvals; licenses and permits being received on favourable terms; sustained labour stability; stability in financial and capital markets; availability of mining equipment and positive relations with local communities and groups. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information are set out in Osisko Metals’ public disclosure record on SEDAR+ (www.sedarplus.ca) under Osisko Metals’ issuer profile.

Although Osisko Metals believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Osisko Metals disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Swiss Water Decaffeinated Coffee Inc. (TSX:SWP) (“Swiss Water” or “the Company”) today announced it will invest $6.2 million to expand production capacity at its Delta, BC facility. The investment will increase production volume by 15% from its current maximum capacity.

Construction is expected to commence in Q1 2027 with no disruption to existing operations. The expansion is scheduled to be completed by June 2027 and operating commercially by July 2027. The Company anticipates internally financing the majority of the investment from operating cash flow, with the balance coming from existing credit lines.

“Decaffeinated coffee drinkers are increasingly demanding that their coffee contain no residual chemical solvents. This continues to drive an industry-wide migration away from chemical decaffeination processes in favour of 100% chemical free products like Swiss Water Process^® coffees. In response, we are excited to announce that, due to growing demand for our decaffeinated coffee and rapidly expanding utilization of our existing production capacity, we will be investing in the expansion of our technologically advanced production facility. This expansion supports Swiss Water’s broader strategy to support existing customer demand, attract new trading partners, and expand into new markets,” said Frank Dennis, Swiss Water’s President & CEO.

Key Details of Expansion

•	Investment:	$6.2 million
•	Location:	Delta, BC
•	Capacity Increase:	15%
•	Completion Date:	June, 2027

Company Profile

Swiss Water Decaffeinated Coffee Inc. is a leading specialty coffee company and a premium green coffee decaffeinator that employs the proprietary Swiss Water^® Process to decaffeinate green coffee without the use of chemical solvents such as methylene chloride. It also owns Seaforth Supply Chain Solutions Inc., a green coffee handling and storage business. Both businesses are located in Delta, British Columbia, Canada.

Swiss Water Decaffeinated Coffee Inc. is a leading specialty coffee company and a premium green coffee decaffeinator which employs the proprietary SWISS WATER^® Process to decaffeinate green coffee without the use of chemicals. It also owns Seaforth Supply Chain Solutions, a green coffee handling and storage business. Both businesses are located in the city of Delta, British Columbia.

For more information, please contact

Iain Carswell, Chief Financial Officer
Swiss Water Decaffeinated Coffee Inc.
Phone: 1-604-420-4050
Email: investor-relations@swisswater.com
Website: investor.swisswater.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking” statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements may include such words as “may”, “will”, “expect”, “believe”, “plan”, “anticipate” and other similar terminology. These statements reflect management’s current expectations regarding future events and operating performance, as well as management’s current estimates, which are based on numerous assumptions and may prove to be incorrect. These statements are neither promises nor guarantees but involve known and unknown risks and uncertainties, including, but not limited to, risks related to processing volumes and sales growth, operating results, the supply of utilities, the supply of coffee and packaging materials, supply of labour force, general industry conditions, commodity price risks, technology, competition, foreign exchange rates, construction timing, costs and financing of capital projects, a potential impact of any pandemics, global and local climate changes, changes in interest rates, inflation, transportation availability, and general economic conditions. The forward-looking statements and financial outlook information contained herein are made as of the date of this press release and are expressly qualified in their entirety by this cautionary statement. Except to the extent required by applicable securities law, Swiss Water undertakes no obligation to publicly update or revise any such statements to reflect any change in management’s expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those described.

TORONTO, ONTARIO, Sept. 16, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce, further to the press release dated September 10, 2026, the closing of the second tranche of a non-brokered private placement of the 15% unsecured convertible debentures (the “Offering”).

In the second tranche of the Offering, the Company issued additional unsecured convertible debentures (the “Debentures”) in an aggregate principal amount of US$4,375,000 million, for an aggregate principal amount, together with the first closing, of US$10,706,250. The terms of the Offering contemplate the issuance of an aggregate principal amount of Debentures up to US$20 million, and the Company anticipates closing one or more additional tranches in the coming weeks. Completion of additional tranches is subject to customary closing conditions, and there can be no assurance that additional tranches will be completed.

As previously disclosed, pursuant to the rules and policies of the Toronto Stock Exchange (the “TSX”), the conversion rights and certain related terms of the Debentures require shareholder approval. The Company has agreed to call a meeting of shareholders (the “Meeting”) within six months to seek the necessary approvals. Additional details will be provided in a forthcoming management information circular, which, once filed, will be available on SEDAR+ at www.sedarplus.ca.

In connection with the second tranche, the Company agreed to pay finders’ fees (a “Finder’s Fee”) on certain subscriptions, which Finder’s Fees may be satisfied in cash or through the issuance of Debentures. Total Finder’s Fees for the second tranche amounted to US$35,000 aggregate principal amount of Debentures and US$100,000 in cash. Any Debentures issued as Finder’s Fees are counted towards the aggregate principal amount outstanding, and the maximum of US$20,000,000.

The Debentures (and Common Shares issuable upon conversion of the Debentures) are subject to a four-month hold period under Canadian securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc. is a holding company operating through its subsidiaries, including Ceapro Inc. (“Ceapro”) and Nualtis^™.

Ceapro is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro’s primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries.

Nualtis is a specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies. Its business model includes pharmaceutical formulation development, analytical and regulatory support services, contract development and manufacturing activities, partner-sponsored development programs and commercial product manufacturing.

The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB^® Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS’ website at www.cosciensbio.com.

Forward-Looking Statements

Certain statements in this news release constitute “forward-looking statements” and/or “forward-looking information” under applicable securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Specific forward-looking statements in this document include, but are not limited to, statements relating to: the expectation of and timing to complete additional tranches of the Offering; the timing to hold the Meeting to receive any required approvals; and the plans, objectives, future outlook and financial position of the Company in general. All forward-looking statements are given pursuant to the “safe harbour” provisions of applicable securities legislation.

The forward-looking statements and financial outlook information contained in this news release are based on a number of material factors, expectations, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, including, without limitation, assumptions regarding: the ability of the Company to complete additional tranches of the Offering and otherwise satisfy its ongoing operations and the availability of capital on acceptable terms; prevailing economic, market, industry and regulatory conditions; and the continued execution of the Company’s strategic plans.

Forward-looking statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statement. Such risk factors are included under “Risk Factors” in our Annual Report and in other documents furnished to the SEC and in our other public disclosure filed under our profile on SEDAR+ at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Many of these factors are beyond our control, and it is not possible for the Company to predict all of these factors, or to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements contained herein, except as required by applicable securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

Issuer Contact:
Peter H. Puccetti
Chief Executive Officer and Chairman of the Board
ppuccetti@cosciensbio.com

Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com

Investor Contact:
IR@cosciensbio.com